News Focus
News Focus
icon url

DewDiligence

03/04/19 10:35 AM

#223858 RE: jmkobers #223857

Something doesn't add up...

Inefficiencies in the valuations of small biotech companies can persist for quite a while. For instance, ENTA was trading at ~$45 as recently as Nov 2017—several months after Mavyret's approval by the FDA and CHMP (#msg-136356320).